KALY Consumer Cannabis Extract Business Reports Growing Revenue Bolstering Its Long Term Biopharmaceutical Strategy
October 01 2019 - 2:39PM
InvestorsHub NewsWire
KALY Consumer Cannabis Extract
Business Reports Growing Revenue Bolstering Its Long Term
Biopharmaceutical Strategy
Dallas, TX --
October 1, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today highlighted the progress of Puration, Inc.
(USOTC:
PURA) reporting today a new European distribution agreement
worth $4 million in potential revenue annually. “What’s good
for PURA, is good for KALY,” said KALY CEO Frederick Ferri.
PURA has the only licenses of KALY’s US Patented Cannabis
Extraction Process for infusing cannabis and hemp extracts into
beverages. KALY licensed the process as part of its consumer
cannabis extraction business. KALY generates revenue from the
direct sale of CBD infused candies under the brand name Hemp4mula
and by licensing its extraction process to companies such as
PURA. KALY also generates revenue in its consumer cannabis
extraction business through the extracting CBD for hemp farming
operations. KALY has recently announced hemp farming CBD
extraction contracts worth a potential $15 million in
revenue. KALY’s consumer cannabis extraction business
continues to grow supporting the company’s much larger long-term
opportunity, its Cannabis Extract Biopharmaceutical
Strategy.
The company has
schedule a presentation for next week on Monday, October 7,
2019 to communicate its latest Cannabis Extract Biopharmaceutical
developments. The last Cannabis Extract Biopharmaceutical
developments update was issued over one month ago. The
company has made some substantial strides forward since that time
and looks forward to sharing the progress with
shareholders.
The update next
week will include the latest information on the company’s CBD
formulation for treating symptoms associated with
Chronic Obstructive Pulmonary
Disease (COPD) and other
similar respiratory conditions. The
formulation for the treatment of symptoms associated with COPD and
other similar respiratory conditions has been derived from the
company’s patented cannabis extraction process. In
conjunction with the research already conducted and the next phase
of research now moving forward, KALY recently filed for a new
patent application specifically on its formulation for symptoms
associated with COPD and other similar respiratory
conditions. KALY also filed for a trademark
on the name RespRx as the brand name for its CBD
formulation to treat the symptoms associated with COPD and other
similar respiratory conditions. The market
for COPD treatment is anticipated to reach $14 billion by
2025.
In the fourth
quarter of last year, 2018, KALY acquired NCMB. In NCMB’s four
years of operations, the company has established a leading position
in the development of plant-derived cannabinoid therapeutics
through a proven drug discovery and patented development
process. The resulting intellectual property portfolio and
the established regulatory and manufacturing expertise have created
a significant opportunity. KALY now has a deep pipeline of
cannabinoid product candidates including four distinct compounds
listed here:
Chronic Obstructive Pulmonary
Disease (COPD) - The
market for COPD treatment is anticipated to reach $14 billion by
2025;
Type 2
Diabetes - The market for
Type 2 Diabetes is expected to be a $64 billion market by
2026;
Cancer Pain
Management - The overall
pain management treatment market is anticipated to reach $83
billion by 2024, and
Epilepsy
- The market for epilepsy treatment is
anticipated to reach $9 billion by 2022.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024